A Prospective, Single-arm, Open-label, Non-interventional, Multicenter to Assess the Safety of BNT162b2 in Domestic Post-marketing Surveillance
Latest Information Update: 07 Oct 2024
At a glance
- Drugs Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- Sponsors Pfizer
- 02 Oct 2024 Planned number of patients changed from 15000 to 18000.
- 07 Dec 2023 Planned number of patients changed from 12000 to 15000.
- 07 Dec 2023 Status changed from recruiting to active, no longer recruiting.